Cargando…

Development of a core evaluation framework of value-added medicines: report 2 on pharmaceutical policy perspectives

BACKGROUND: A core evaluation framework that captures the health care and societal benefits of value added medicines (VAMs, also often called repurposed medicines) was proposed in Report 1, aiming to reduce the heterogeneity in value assessment processes across countries and to create incentives for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaló, Zoltán, Petykó, Zsuzsanna Ida, Fricke, Frank-Ulrich, Maniadakis, Nikos, Tesař, Tomáš, Podrazilová, Kateřina, Espin, Jaime, Inotai, András
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280561/ https://www.ncbi.nlm.nih.gov/pubmed/34266465 http://dx.doi.org/10.1186/s12962-021-00296-2

Ejemplares similares

Development of a core evaluation framework of value-added medicines: report 1 on methodology and findings
por: Petykó, Zsuzsanna Ida, et al.
Publicado: (2021)

Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals – an application on improving tender decision making in Indonesia
por: Inotai, Andras, et al.
Publicado: (2018)

The Impact of Reimbursement Practices on the Pharmaceutical Market for Off-Patent Medicines in Slovakia
por: Tesar, Tomas, et al.
Publicado: (2021)

Assessing the Consequences of External Reference Pricing for Global Access to Medicines and Innovation: Economic Analysis and Policy Implications
por: Incze, András, et al.
Publicado: (2022)

How Changes in Reimbursement Practices Influence the Financial Sustainability of Medicine Policy: Lessons Learned from Slovakia
por: Tesar, Tomas, et al.
Publicado: (2019)

Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts
por: Inotai, Andras, et al.
Publicado: (2018)

Attempt to increase the transparency of fourth hurdle implementation in Central-Eastern European middle income countries: publication of the critical appraisal methodology
por: Inotai, András, et al.
Publicado: (2012)

Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review
por: Kawalec, Paweł, et al.
Publicado: (2017)

Potential Cost-Savings From the Use of the Biosimilars in Slovakia
por: Tesar, Tomas, et al.
Publicado: (2020)

Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status
por: Maniadakis, N., et al.
Publicado: (2017)

Guidance on using real-world evidence from Western Europe in Central and Eastern European health policy decision making
por: Németh, Bertalan, et al.
Publicado: (2023)

Recommendations to overcome barriers to the use of artificial intelligence-driven evidence in health technology assessment
por: Zemplényi, Antal, et al.
Publicado: (2023)

Overview on Patient Centricity in Cancer Care
por: Narbutas, Šarunas, et al.
Publicado: (2017)

Identifying Patient Access Barriers for Tumor Necrosis Factor Alpha Inhibitor Treatments in Rheumatoid Arthritis in Five Central Eastern European Countries
por: Inotai, András, et al.
Publicado: (2020)

Framework for Patient Experience Value Elements in Rare Disease: A Case Study Demonstrating the Applicability of Combined Qualitative and Quantitative Methods
por: McQueen, R. Brett, et al.
Publicado: (2022)

Cost-Utility Analysis of Heberprot-P as an Add-on Therapy to Good Wound Care for Patients in Slovakia with Advanced Diabetic Foot Ulcer
por: Tesar, Tomas, et al.
Publicado: (2017)

Proposal for capturing patient experience through extended value frameworks of health technologies
por: Inotai, András, et al.
Publicado: (2021)

Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary
por: Vokó, Zoltán, et al.
Publicado: (2012)

The EEC at the end of the seventies : Western European integration in the new world economic environment /
por: Inotai, András
Publicado: (1979)

Recommendations for patient involvement in health technology assessment in Central and Eastern European countries
por: Jakab, Ivett, et al.
Publicado: (2023)

Epidemiology, health-related quality of life and economic burden of binge eating disorder: a systematic literature review
por: Ágh, Tamás, et al.
Publicado: (2015)

The exposure of nonsmoking and smoking mothers to environmental tobacco smoke during different gestational phases and fetal growth.
por: Dejmek, Jan, et al.
Publicado: (2002)

Pharmaceutical Policy Part 2 Pharmaceutical engagement and policy development: a framework for influence
por: Morrow, Norman C
Publicado: (2015)

Shaping Pharmaceutical Tenders for Effectiveness and Sustainability in Countries with Expanding Healthcare Coverage
por: Maniadakis, Nikolaos, et al.
Publicado: (2018)

Public Policy and Pharmaceutical Innovation
por: Grabowski, Henry G.
Publicado: (1982)

Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan
por: Gialama, Fotini, et al.
Publicado: (2013)

Stakeholder driven development of a multi-criteria decision analysis tool for purchasing off-patent pharmaceuticals in Kuwait
por: Abdullah, Ali Hadi, et al.
Publicado: (2019)

Pharmaceutical policies in Australia and New Zealand
por: Babar, Zaheer-Ud-Din
Publicado: (2015)

The Pharmaceutical Company Approach to Antibiotic Policies
por: White, Anthony R.
Publicado: (2005)

Microbial factories for recombinant pharmaceuticals
por: Ferrer-Miralles, Neus, et al.
Publicado: (2009)

Pharmaceutical policy Part 1 The challenge to pharmacists to engage in policy development
por: Morrow, Norman C
Publicado: (2015)

Contribution of clinical trials to gross domestic product in Hungary
por: Kaló, Zoltán, et al.
Publicado: (2014)

Self-reported prevalence of atherothrombosis in a general population sample of adults in Greece; A telephone survey
por: Maniadakis, Nikos, et al.
Publicado: (2011)

Pharmaceutical pricing and reimbursement policies: perspectives for the future
por: Gray, Andrew L
Publicado: (2015)

Challenges and opportunities for pharmaceutical pricing and reimbursement policies
por: Vogler, Sabine, et al.
Publicado: (2015)

Affordable innovation: future directions in pharmaceutical policy
por: Hill, Suzanne R
Publicado: (2015)

Editorial: Pharmaceutical policy, impact and health outcomes
por: Kwon, Hye-Young, et al.
Publicado: (2023)

Implementation of coverage with evidence development schemes for medical devices: A decision tool for late technology adopter countries
por: Kovács, Sandor, et al.
Publicado: (2022)

Core competencies for pharmaceutical physicians and drug development scientists
por: Silva, Honorio, et al.
Publicado: (2013)

Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries
por: Kamusheva, Maria, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_175mk54s3ginoufurm9js9ukal